Peer Review reports
From: Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials
Original Submission | ||
---|---|---|
26 Mar 2021 | Submitted | Original manuscript |
3 Apr 2021 | Author responded | Author comments - Eva Maria Gamper |
Resubmission - Version 2 | ||
3 Apr 2021 | Submitted | Manuscript version 2 |
21 Apr 2021 | Author responded | Author comments - Eva Maria Gamper |
Resubmission - Version 3 | ||
21 Apr 2021 | Submitted | Manuscript version 3 |
5 May 2021 | Reviewed | Reviewer Report |
15 May 2021 | Reviewed | Reviewer Report |
27 May 2021 | Author responded | Author comments - Eva Maria Gamper |
Resubmission - Version 4 | ||
27 May 2021 | Submitted | Manuscript version 4 |
16 Jun 2021 | Author responded | Author comments - Eva Maria Gamper |
Resubmission - Version 5 | ||
16 Jun 2021 | Submitted | Manuscript version 5 |
7 Jul 2021 | Author responded | Author comments - Eva Maria Gamper |
Resubmission - Version 6 | ||
7 Jul 2021 | Submitted | Manuscript version 6 |
Publishing | ||
16 Jul 2021 | Editorially accepted | |
7 Oct 2021 | Article published | 10.1186/s12885-021-08609-7 |
You can find further information about peer review here.